First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group
Kenichi Kobayashi(Shiga University of Medical Science), T. Nukiwa(Tohoku University), Hiroshi Isobe, Akira Inoue(Tohoku University Hospital), Satoshi Oizumi(Hokkaido University), Yasuo Saijo(Ho Chi Minh City International University), Shunichi Sugawara(Sendai Kousei Hospital), K. Hagiwara, Makoto Maemondo(Miyagi Prefectural Hospital Organization), S. Morita(Tohoku University), Akihiko Gemma(Nippon Medical School)
Cited by 63
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695